"Thromboxane A2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS).
| Descriptor ID |
D013928
|
| MeSH Number(s) |
D10.251.355.255.100.825.800 D10.251.355.310.166.971.800
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thromboxane A2".
Below are MeSH descriptors whose meaning is more specific than "Thromboxane A2".
This graph shows the total number of publications written about "Thromboxane A2" by people in this website by year, and whether "Thromboxane A2" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Thromboxane A2" by people in Profiles.
-
Increased peripheral vascular disease risk progressively constrains perfusion adaptability in the skeletal muscle microcirculation. Am J Physiol Heart Circ Physiol. 2016 Feb 15; 310(4):H488-504.
-
Impaired contractile response of human peripheral arterioles to thromboxane A-2 after cardiopulmonary bypass. Surgery. 2011 Aug; 150(2):263-71.
-
Aspirin resistance with genetic dyslipidemia: contribution of vascular thromboxane generation. Physiol Genomics. 2010 Aug; 42(3):331-41.
-
Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature. Ann Pharmacother. 2010 May; 44(5):851-62.
-
Increased arachidonic acid-induced thromboxane generation impairs skeletal muscle arteriolar dilation with genetic dyslipidemia. Microcirculation. 2008 Oct; 15(7):621-31.
-
Prostaglandins, cyclo-oxygenase inhibitors, and thromboxane synthetase inhibitors in the pathogenesis of multiple systems organ failure. Crit Care Clin. 1989 Apr; 5(2):303-14.